MLTX Q4 2022 Earnings — MoonLake Immunotherapeutics Revenue & Financial Results | Market Cap Arena

MLTXMoonLake Immunotherapeutics

$1B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$17M

Net Income

-$2M

EPS (Diluted)

$-0.05

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$77M

Total Liabilities

$8M

Stockholders' Equity

$49M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$2,487	+100.0%
Operating Income	-$17M	-$14M	-16.9%
Net Income	-$2M	-$14M	+86.5%